-
Vetter Contributes to Commercial Launches of Eight Customer Products in 2023
Biotech Newswire
February 18, 2024
February 14, 2024 Vetterannounces the successful commercialization of eight customer drug products as of the completion of 2023.
-
Vetter Performs Extraordinarily with Six Wins in the 12th Annual CDMO Leadership Awards
PharmaSources
April 04, 2023
Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), earned the esteemed 2023 CDMO Leadership Awards in all six core categories – quality, expertise, reliability, capabilities, compatibility and service.
-
Vetter’s Clinical Facility Demonstrates Success with Five Client Products Now on the Market
PharmaSources
February 02, 2023
Both the US Skokie and European Rankweil sites address customer needs in early-phase drug development
-
Rentschler Biopharma and Vetter Unveil Xpert Alliance, a Joint Visualization of their Successful Strategic Collaboration
b3cnewswire
March 30, 2022
Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations...
-
Vetter’s New Clinical Manufacturing Site Now Officially Authorized
B3Cnewswire
January 20, 2022
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has received the manufacturing authorization for its new site in Rankweil, Austria.
-
Vetter Receives Manufacturing Authorization for New Site
contractpharma
January 19, 2022
First customer audits already completed.
-
Vetter Wins Frost & Sullivan’s 2021 Global Customer Value Leadership Award, and Looks Back on a Stable Year Under Ongoing Pandemic Circumstances
B3Cnewswire
December 08, 2021
Vetter, a leading global Contract Development and Manufacturing Organization (CDMO), has been awarded the Frost & Sullivan's 2021 Global Customer Value Leadership Award in the aseptic fill & finish market...
-
Vetter's Contribution to Climate Protection: Corporate Sites Around the World are CO2-Neutral
B3Cnewswire
September 23, 2021
The “Green Deal” initiated by the European Commission aims at reducing the net emissions of greenhouse gases to zero across the EU by 2050, thereby making the European continent climate-neutral.
-
Vetter’s New Clinical Mfg. Site Now Fully Integrated
contractpharma
July 22, 2021
Vetter, a global CDMO, has further invested in additional capacity to meet the growing global demand for clinical manufacturing for injectable drug products.
-
Vetter’s New Clinical Manufacturing Site Now Fully Integrated
b3cnewswire
July 22, 2021
A growing number of pharmaceutical and biotech companies are seeking clinical manufacturing partners that provide strategic support and comprehensive resources for their development process of new, promising injectable drug products.